Sugi Predict

Sugi Predict / Compounds / SCHEMBL184868

SCHEMBL184868

SCHEMBL184868

COC(=O)c1ccc(CN)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LOXL2 Q9Y4K0 2/20 1.00
▸ MAPT P10636 2/20 0.62
▸ CYP4A11 Q02928 2/20 0.59
▸ CYP4F2 P78329 1/20 0.58
▸ CA1 P00915 4/20 0.57
▸ CA2 P00918 4/20 0.57
▸ CA12 O43570 2/20 0.57
▸ CA9 Q16790 2/20 0.57
▸ CA14 Q9ULX7 2/20 0.57
▸ TDP1 Q9NUW8 1/20 0.57
▸ CA7 P43166 1/20 0.57
▸ HDAC3 O15379 1/20 0.57
▸ HDAC6 Q9UBN7 1/20 0.57
▸ NCOR2 Q9Y618 1/20 0.57
▸ TSHR P16473 2/20 0.54
▸ MEN1 O00255 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ ALDH1A1 P00352 2/20 0.52
▸ KDM4E B2RXH2 1/20 0.51
▸ NPC1 O15118 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL210547 0.98 LOXL2 (0.96) LOXL2MAPTCYP4A11CYP4F2CA1
SCHEMBL6677665 0.94 LOXL2 (0.89) LOXL2MAPTCYP4A11CYP4F2CA1
Sulfuric Acid SCHEMBL2363547 0.93 LOXL2 (0.86) LOXL2MAPTCYP4A11CYP4F2CA1
SCHEMBL12636516 0.91 LOXL2 (0.83) LOXL2MAPTCYP4A11CYP4F2CA1
SCHEMBL28267713 0.91 LOXL2 (0.83) LOXL2MAPTCYP4A11CYP4F2CA1
SCHEMBL7251467 0.91 LOXL2 (0.83) LOXL2MAPTCYP4A11CYP4F2CA1
SCHEMBL28117998 0.89 LOXL2 (0.80) LOXL2MAPTCYP4A11CA1CA2
Hydrochloric Acid SCHEMBL15239626 0.88 LOXL2 (0.77) LOXL2MAPTCYP4A11CYP4F2TDP1
Hydrochloric Acid SCHEMBL15239627 0.88 LOXL2 (0.77) LOXL2MAPTCYP4A11CYP4F2TDP1
Trifluoroacetic Acid SCHEMBL28281967 0.88 LOXL2 (0.77) LOXL2MAPTCYP4A11CYP4F2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1562 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119504437-A Method for denitrification alkylation of aromatic methylamine 中国科学技术大学 2025-02-25 — — CN claimed
CN-118791483-A 1H-pyrazolo [3,4-b ] pyridine derivative and preparation method and application thereof 郑州大学 2024-10-18 — — CN claimed
CN-118619922-A Hydroxamic acid compound, and preparation method and application thereof 郑州大学 2024-09-10 — — CN claimed
CN-118480006-A Novel pyridazinone compound and preparation method and application thereof 郑州大学 2024-08-13 — — CN claimed
CN-114890947-B Aromatic heterocyclic compound containing quinoline structural unit, and preparation method and application thereof 郑州大学 2024-07-16 — — CN claimed
CN-118239885-A Synthesis method of cidamine 常州合全药业有限公司 2024-06-25 — — CN claimed
WO-2023215742-A2 ENZYMATIC REDUCTION OR REDUCTIVE AMINATION OF ARYL AND HETEROCYCLIC CARBOXYLIC ACIDS AND ALDEHYDES KUNJAPUR ADITYA (US) 2023-11-09 — — WO claimed
CN-116854688-A HDAC6 inhibitor, preparation method thereof and application thereof in resisting tumor and pulmonary fibrosis 四川大学 2023-10-10 — — CN claimed
CN-114075187-B Carbonyl pyrazole antitumor compound as well as preparation method and application thereof 山东大学 2023-05-12 — — CN claimed
CN-113831338-A Histone deacetylase inhibitor and preparation method and application thereof 中国海洋大学 2021-12-24 — — CN claimed
EP-1368323-A1 PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS Warner-Lambert Company LLC (US) 2003-12-10 — — EP claimed
EP-1362033-A1 PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS Warner-Lambert Company LLC (US) 2003-11-19 — — EP claimed
EP-1146788-A4 AMIDE DERIVATIVES FOR ANTIANGIOGENIC AND/OR ANTITUMORIGENIC USE UNIV VANDERBILT (US) 2003-09-10 — — EP claimed
US-20020161000-A1 Pyridine matrix metalloproteinase inhibitors WARNER-LAMBERT COMPANY 2002-10-31 — — US claimed
US-20020151555-A1 Pyrimidine matrix metalloproteinase inhibitors BARVIAN NICOLE CHANTEL (US) 2002-10-17 — — US claimed
WO-2002064568-A1 PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 — — WO claimed
WO-2002064571-A1 PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 — — WO claimed
EP-1146788-A1 AMIDE DERIVATIVES FOR ANTIANGIOGENIC AND/OR ANTITUMORIGENIC USE Vanderbilt University (US) 2001-10-24 — — EP claimed
WO-2000040088-A1 AMIDE DERIVATIVES FOR ANTIANGIOGENIC AND/OR ANTITUMORIGENIC USE VANDERBILT UNIVERSITY (US) 2000-07-13 — — WO claimed
US-4048222-A P-AMINOMETHYLBENZOIC ACID, RUTHENIUM CATALYST KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JA) 1977-09-13 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161000-A1 Pyridine matrix metalloproteinase inhibitors MMP13, MMP3, MMP11 LOXL2 728/4885MAPT 4761/4885CYP4A11 328/4885
US-20020151555-A1 Pyrimidine matrix metalloproteinase inhibitors MMP13, MMP3, MMP11 LOXL2 1198/4885MAPT 4761/4885CYP4A11 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.